Andere Sprachen Capricor Therapeutics, Inc.

Aktien

A2PLU4

US14070B3096

CAPR

Realtime-Estimate Cboe BZX Andere Börsenplätze 20:29:39 23.05.2024			% 5 Tage	% 1. Jan.
6,06 ^USD	-3,04 %		+7,89 %	+24,44 %

17.05.	CAPRICOR THERAPEUTICS, INC. : Bewertung von Oppenheimer kaufen	ZM
13.05.	Transcript : Capricor Therapeutics, Inc., Q1 2024 Earnings Call, May 13, 2024

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Capricor: Q1 Earnings Snapshot	13.05.
Earnings Flash (CAPR) CAPRICOR THERAPEUTICS Posts Q1 Revenue $4.9M, vs. Street Est of $9.7M	13.05.
Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update	13.05.
Capricor Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13.05.
Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting	09.05.
Capricor Therapeutics, Inc. to Present Exosome Platform Updates At the American Society of Gene and Cell Therapy 27Th Annual Meeting	09.05.
Capricor Therapeutics to Present at Upcoming Scientific and Medical Conferences	08.05.
Capricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13	06.05.
Capricor Therapeutics Gets Another Type-B Meeting With FDA for Duchenne Muscular Dystrophy Investigational Drug	24.04.
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy	24.04.
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy	24.04.
Capricor Therapeutics to Present at Upcoming Investor Conferences	21.03.
Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference	06.03.
Capricor Therapeutics, Inc. to Present Positive 24-Month Results from its HOPE-2 Open-Label Extension Study at 2024 Muscular Dystrophy Association Clinical & Scientific Conference	06.03.
Capricor: Q4 Earnings Snapshot	29.02.
Earnings Flash (CAPR) CAPRICOR THERAPEUTICS Posts Q4 Revenue $12.1M, vs. Street Est of $10.6M	29.02.
Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	29.02.
Capricor Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29.02.
Capricor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29.02.
Sector Update: Health Care Stocks Ease Late Afternoon	27.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Capricor Therapeutics, Inc.

Aktien

A2PLU4

US14070B3096

CAPR

Andere Sprachen

Filter